DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology

0
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...

Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.

0
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....

Popular News

MAKE IT MODERN

LATEST REVIEWS

Inovio Pharmaceuticals Inc. (NASDAQ:INO) Signs Deal With Kaneka Eurogentec For Manufacture...

0
Inovio Pharmaceuticals Inc. (NASDAQ:INO) has entered a manufacturing deal with Japan's Kaneka Corp to manufacture its COVID-19 vaccine candidate. The US vaccine maker didn't...

MAKE IT MODERN

PERFORMANCE TRAINING

Apellis Pharmaceuticals Inc (NASDAQ:APLS) Reveals 18-month data From Its Phase 1b APL2-103 study

0
Apellis Pharmaceuticals Inc (NASDAQ:APLS) recently 18 months’ worth of data collected through its Phase 1b APL2-103 study evaluating pegcetacoplan as a treatment for advanced...

Cellect Biotechnology Ltd – ADR (NASDAQ:APOP) Receives an Approval of a Pivotal Patent for...

0
Every successful medicinal activity requires mass production of quality stem cells. This is what avails regenerative medicine to the public the need occasioned the...

Viking Therapeutics (VKTX): Is This Weight Loss Drug Contender Worth Buying on the Dip?

0
Viking Therapeutics (NASDAQ: VKTX) has made significant waves in the biotechnology sector this year, emerging as a formidable contender in the booming...

Can-Fite (NYSEAMERICAN:CANF) Submits Investigational New Drug for a Phase II Study of Piclidenoson in...

0
Can-Fite (NYSEAMERICAN:CANF) has been using its capabilities to develop an innovative pipeline of patented compounds aimed at treating autoimmune-inflammatory and liver diseases. However, with...

Clovis Oncology Inc. (NASDAQ:CLVS) Reports Q3 2020 Results With Rubraca Sales Of $38.8 Million

0
Clovis Oncology Inc. (NASDAQ:CLVS) has announced results for Q3 2020 and also offers an update on its clinical development programs and commercial outlook for...

MAKE IT MODERN

POPULAR

romabet mahbet پین باهیس bettingmagazine.org بت کارت یاس بت yekbet megapari onjabet alvinbet betboro betfa بت فوروارد 1xbet 1win betwinner 4shart.com 1xbetgiris.cam وان کیک بت وین بت ریتزوبت 1xbet-ir.com.co وان ایکس بت بت فوروارد